New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH

    NEXT STORY
    CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
    PREV STORY
    Vaxcyte Announces Pricing of Upsized Initial Public Offering
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

    Efficacy and safety continue to be a major advantage, with a very high response ...

    author_avatar
    NASDAQ Market News

    Skylight Health Group’s Common Shares to Begin Trading on Nasdaq on Monday, June 7, 2021 Under Symbol SLHG

    author_avatar
    NASDAQ Market News

    TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

    author_avatar
    NASDAQ Market News